The epigenetic mark of O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation is also taken under consideration for glioblastoma patients, as it was proven to correlate with survival, following temolozomide treatment [18]. This evidence concerns the gene MGMT and glioblastoma.